ASCO 2025 | Outpatient toxicity following lifileucel in advanced melanoma
James Smithy, MD, MHS, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of a retrospective analysis assessing outpatient treatment-related toxicity in patients with advanced melanoma discharged after lifileucel therapy. The study reports low rates of severe adverse events and treatment-related readmissions post-discharge. A notable proportion required outpatient blood product support. These findings overall highlight the generally manageable safety profile of lifileucel beyond hospitalization. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the inpatient toxicity with lifileucel has been well characterized, but I think there are a lot of open questions on how to manage these patients after they go home from the hospital. So we looked at a retrospective series of 51 patients treated with lifileucel both in the investigational and standard of care setting, and basically documented new emergent toxicity, hospital readmissions, and blood product transfusions that were required after discharge...
So the inpatient toxicity with lifileucel has been well characterized, but I think there are a lot of open questions on how to manage these patients after they go home from the hospital. So we looked at a retrospective series of 51 patients treated with lifileucel both in the investigational and standard of care setting, and basically documented new emergent toxicity, hospital readmissions, and blood product transfusions that were required after discharge. So what we found in this cohort was relatively low rates of hospital readmission and new grade 3 toxicities. Only four patients were readmitted to the hospital for reasons related to toxicity and only two patients had new grade 3 new adverse events emerge. In terms of blood products, about one in four patients did require blood products after hospital discharge, but a lot of those patients had been receiving blood products in the hospital and that was expected per their discharge criteria.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Bristol-Myers Squibb; IO Biotech; Iovance Biotherapeutics
Research Funding – Daiichi Sankyo (Inst); IO Biotech (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses – Immatics
